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AbstrACt 
Introduction Human papillomaviruses (HPVs) are 
responsible for one-third of all cancers caused by 
infections. Most HPV studies focus on chronic infections 
and cancers, and we know little about the early stages of 
the infection. Our main objective is to better understand 
the course and natural history of cervical HPV infections in 
healthy, unvaccinated and vaccinated, young women, by 
characterising the dynamics of various infection-related 
populations (virus, epithelial cells, vaginal microbiota 
and immune effectors). Another objective is to analyse 
HPV diversity within hosts, and in the study population, in 
relation to co-factors (lifestyle characteristics, vaccination 
status, vaginal microbiota, human genetics).
Methods and analysis The PAPCLEAR study is a single 
center longitudinal study following 150 women, aged 
18–25 years, for up to 2 years. Visits occur every 2 
or 4 months (depending on HPV status) during which 
several variables are measured, such as behaviours 
(via questionnaires), vaginal pH, HPV presence and viral 
load (via qPCR), local concentrations of cytokines (via 
MesoScale Discovery technology) and immune cells (via 
flow cytometry). Additional analyses are outsourced, such 
as titration of circulating anti-HPV antibodies, vaginal 
microbiota sequencing (16S and ITS1 loci) and human 
genotyping. To increase the statistical power of the 
epidemiological arm of the study, an additional 150 women 
are screened cross-sectionally. Finally, to maximise the 
resolution of the time series, participants are asked to 
perform weekly self-samples at home. Statistical analyses 
will involve classical tools in epidemiology, genomics and 
virus kinetics, and will be performed or coordinated by the 
Centre National de la Recherche Scientifique (CNRS) in 
Montpellier.
Ethics and dissemination This study has been 
approved by the Comité de Protection des Personnes Sud 
Méditerranée I (reference number 2016-A00712-49); by 
the Comité Consultatif sur le Traitement de l’Information 
en matière de Recherche dans le domaine de la Santé 
(reference number 16.504); by the Commission Nationale 
Informatique et Libertés (reference number MMS/ABD/
AR1612278, decision number DR-2016–488) and by 
the Agence Nationale de Sécurité du Médicament et des 
Produits de Santé (reference 20160072000007). Results 
will be published in preprint servers, peer-reviewed 
journals and disseminated through conferences.
trial registration number NCT02946346; Pre-results.
IntroduCtIon
Epidemiology of human papillomavirus genital 
infections in young adults and public health 
implications
Infections by human papillomaviruses 
(HPVs) are likely the most common sexu-
ally transmitted infection (STI) globally. It is 
often estimated that, worldwide, more than 
80% of sexually active individuals will be 
strengths and limitations of this study
 ► Short  time interval between the visits (every 
2 months for infected women) and additional 
self-sampling every week at home.
 ► The combination of virological (virus load), immu-
nological (cytokine concentrations and immune cell 
percentages) and environmental (vaginal microbiota 
composition, pH) measurements at each visit.
 ► A limitation is that the density of the follow-up limits 
the number of participants (n=150) which can affect 
the power of epidemiological analyses.
 ► We complement the longitudinal study with a 
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infected by an HPV type.1 2 In France, a study performed 
in 2013 in the Paris area estimated the prevalence of HPV 
genital infections to be 25% in women below 25 years of 
age.3 In the area of Montpellier (France), the prevalence 
of oncogenic HPVs (also referred to as ‘high-risk’ (HR) 
HPVs) in pregnant women aged 16–42 years was close 
to 20%.4 These numbers are consistent with worldwide 
estimates according to which HPVs are most prevalent in 
women under 25 years of age, with an estimated overall 
prevalence of 24%.5
Fortunately, the vast majority of infections by HPVs are 
asymptomatic and benign. Even for HPV16, which is prob-
ably the most oncogenic human virus, only a minority of 
infections (less than 10%) become persistent,6 and then a 
minority of these (12%) progress to cancer if untreated.1 7 
Indeed, it is estimated that approximately 70%–100% of 
infections by HPVs are cleared within 12–24 months, 
with strong differences between virus types.6 8–10 Recent 
studies suggest that primo-infections could be shorter in 
young girls11 but, in general, there are many unknowns 
about the biology of non-persisting infections.12
Our lack of knowledge partly comes from the fact that 
in vaccine trials, from which most of the data on infec-
tion duration originate, participants are followed every 
6 months for several years.6 8 10 13 This frequency is suffi-
cient to estimate the time to clearance (or persistence) 
but it is not precise enough to understand the within-host 
dynamics, often referred to as ‘kinetics’,14 of infections 
that last on average 6–24 months. Arbitrarily, after 24 
months, an infection is often considered to be persistent.15
Some factors have been shown to correlate with 
persistence (eg, immunosuppression, smoking and co-in-
fection with other STIs16) but we do not know how these 
affect viral kinetics. Also, some changes in the interactions 
between virus and the host immunity appear to be related 
to persistence and disease progression17–20 but, again, we 
do not know the underlying interactions between the 
viruses, the host target cells, and the immune response 
in acute infections.12 Finally, it has been argued that the 
vaginal microbiota may differ between HPV-infected and 
HPV-uninfected women21 and that specific microbiota 
composition may interact with HPV detection.22 However, 
it is difficult to disentangle the cause and the conse-
quence. For instance, does the microbiota composition 
change after the establishment of an HPV infection, or do 
certain microbiota compositions increase susceptibility to 
HPV infection?
A better understanding of the within-host infection 
dynamics and of the determinants of clearance and 
persistence of viral infection is particularly important 
in the context of vaccination.23–26 Indeed, the long-term 
efficacy of the anti-HPVs vaccines at the population level 
will largely depend on the within-host viral dynamics 
because, ultimately, most selective pressures on viral 
populations occur via the immune response.27 Further-
more, a better understanding of acute HPV infections 
can shed new light on issues related to latency, fertility or 
immunotherapies.12
Prevention strategies and treatment
Treatment
Since most infections by HPVs are benign in young adults 
and clear within six to 24 months, the current standard 
of care is to avoid over-treatment, even in the presence 
of cervical lesions.28 Clinical interventions (colposco-
pies, biopsies and surgery) are less often performed 
with young women (<25 years) and only for high-grade 
(precancerous) lesions (cervical intraepithelial neoplasia 
grade 2 (CIN-2) or more). Low-grade lesions (CIN-1) are 
not systematically treated but rather monitored yearly to 
detect any progression to high-grade lesions.
Genital warts caused by non-oncogenic HPVs (often 
referred to as ‘low-risk’ (LR) HPVs) can be removed by 
surgery or treated with bi- and trichloroacetic acid, cryo-
therapy or other treatments.29
HPV vaccination
There are currently three licensed vaccines: a biva-
lent vaccine (Cervarix) targeting HPV16 and HPV18 
(together accounting for 70% of cervical cancers1), a 
quadrivalent vaccine (Gardasil) that additionally targets 
HPV6 and HPV11 (non-oncogenic, but highly preva-
lent and associated to benign proliferative lesions) and, 
since 2014, a nonavalent vaccine (Gardasil 9) that targets 
five more oncogenic types (HPV31, HPV33, HPV45, 
HPV52 and HPV58, which altogether account for 20% 
of cervical cancers25). These vaccines succeed in eliciting 
a protective immune response against new infections by 
the targeted viruses, and are used throughout the world, 
although with wide variation in coverage (for reviews, 
see, e.g, refs30 31).
Vaccination campaigns in France started in 2006 but 
with limited coverage: it reached 28.5% in 200832 and 
has been decreasing ever since.33 The vaccine is recom-
mended for girls from 11–14 years of age, currently with a 
vaccination scheme of two doses with a 6-month interval. 
A catch-up is organised for girls aged 15–19 years, with a 
three-dose vaccination scheme. Vaccination is reimbursed 
by the French Social Security but is not mandatory. It is 
also recommended for men who have sex with men as 
well as for immuno-compromised people.33 Vaccination 
is now the primary prevention strategy against cervical 
cancers.
Screening
In France, the secondary prevention strategy against 
cervical cancer is routine individual cytology-based 
screening for precancerous and cancerous cervical 
lesions in women between 25 and 65 years old. Cytology 
can also be performed in younger women if they report 
risk factors for cervical cancer (multiple partners, chronic 
STIs or HIV infection33). Detection of oncogenic HPVs 
is proposed for triage in case of abnormal cytology (ie, 
high-grade or low-grade squamous intraepithelial lesion 
(HSIL and LSIL, respectively) or atypical squamous cells 
of undetermined significance (ASCUS)).
 o
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Primary objectives
The first primary objective of this cohort study is to deci-
pher the kinetics and ecology of cervical HPV infections 
in healthy young women, that is, follow the population 
dynamics of the virus, the target epithelial cells, the 
vaginal microbiota, and the immune effectors.
The second primary objective is to characterise the 
diversity of genital HPVs in young women in the region 
of Montpellier in relationship with their lifestyle, vaccina-
tion status, vaginal microbiota and human genetics.
secondary objectives
A secondary objective is to characterise the acquisition 
and clearance dynamics of cervical HPV infections as a 
function of viral diversity, host immunity, vaginal micro-
biota and human genetics.
A final objective is to investigate variations in genetic 
diversity of HPVs during cervical infections.
MEthods And AnAlysIs
Participants
The study population is composed of young women at 
risk of HPV infection. The age class was chosen because 
it exhibits high HPV prevalence (24% worldwide5 and 
approximately 25% in France3). Inclusion of younger 
women would have raised technical issues because of the 
requirement for parental consent.
Women are recruited through a social media page, and 
through posters and leaflets distributed at the universi-
ties in Montpellier and at the Montpellier STI screening 
centre (Centre Gratuit d’Information de Dépistage et de Diag-
nostic, CeGIDD). The composition of the population 
visiting the CeGIDD has already been documented in an 
earlier study.34 In total, the centre is visited by approxi-
mately 3,000 women per year, the majority of which are 
under 25 years of age (80%). Approximately 40% of the 
attendants report three or more partners over the last 12 
months and approximately 50% report using adequate 
behaviour for prevention against HIV.
Since all participants are healthy, they are referred to as 
participants rather than patients. As in any longitudinal 
study, ensuring participant commitment is challenging. 
To achieve this goal, we have set up a compensation of 
€40 per visit and an additional €10 in case of a complete 
follow-up. Furthermore, participants who have answered 
a sufficient number of questionnaires and brought back 
a sufficient number of self-samples get a €100 bonus at 
the end. Overall, a participant performing 12 return visits 
would gain a total compensation of €650.
Inclusion criteria
Participants are women from 18 to 25 years old living 
in the metropolitan area of Montpellier. They must be 
sexually active with at least one new partner over the last 
12 months. These criteria are fixed to maximise the inci-
dence of new HPV infections. Participants must be able 
to and willing to give written informed consent: they must 
sign an informed consent form, understand the require-
ments for the study and be affiliated to a French social 
security scheme (which is a state requirement).
Women cannot be included in the study if they have 
a history of HPV-associated pathology (genital warts or 
cervical lesions), if they are pregnant or intending to 
become pregnant in the coming year, infected by HIV, 
undergoing (or planning to undergo) intense medical 
treatment (biotherapy, chemotherapy, immunosuppres-
sion), planning on moving outside the Montpellier metro-
politan area within the next 18 months, in a dependency 
or employment with the sponsor or the investigator, if 
they participated in a clinical trial involving administra-
tion of drugs within the last 4 weeks or if they belong to a 
vulnerable group (e.g., children, adults with physical or 
mental disabilities).
design/setting
This study has a longitudinal component aimed at deci-
phering within-host dynamics and a cross-sectional 
component aimed at understanding the diversity of HPV 
infections in young adults in the area of Montpellier, 
France. The general structure of the study is shown in 
figure 1.
If a woman fits the main inclusion criteria, she can go 
through an inclusion visit (V1) with a physician (gynae-
cologist or midwife) at the CeGIDD. During this visit, 
the study investigator presents the study and checks all 
inclusion criteria before asking the participant to read 
and sign the informed consent form. Participants then 
undergo a medical consultation during which a number 
of samples are collected (see below). They then fill out 
health and lifestyle questionnaires and are given cotton-
flocked swabs for self-sampling at home the next visit, 
along with instructions on how to fill in weekly question-
naires through an online form (these are performed 
throughout the study).
An appointment is scheduled 4 weeks later for the 
results visit (V2), where the cervical cytology results are 
communicated. Additional samples are collected and self-
sample swabs for home collection are provided.
The next return visits (Vi, where i>2) are as follows:
 ► Participants with a positive HPV detection test (see 
below), that is, infected by an Alphapapillomavirus, at 
V1  join the HPV positive (HPV+) arm of the study with 
return visits scheduled every 2 months.
 ► Participants with a negative HPV detection test at V1 
join the HPV negative (HPV-) arm with return visits 
scheduled every 4 months.
 ► HPV- participants infected by an Alphapapillomavirus 
move to the HPV+ arm.
Intervals between visits are based on earlier results 
showing that HPV infections last from 9 to 18 months on 
average depending on the HPV type6 8–10 and that a total 
follow-up of 4 months yields results that are difficult to 
analyse.22 The longer interval in the HPV- arm is based 
on the estimated incidence for HPV genital infections in 
young women which is greater than 30%.35 36
 o
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Participants in the HPV- arm are followed until month 
32 of the study.
Participants in the HPV+ arm are followed until they 
clear the infection or until they have been infected for 
24 months (after which we consider that the infection 
is persistent). Clearance is defined as being negative at 
two visits in a row for the first HPV type detected in the 
follow-up.
In between these visits to the CeGIDD, participants are 
asked to perform regular (every week for HPV+ and every 
second week for HPV-) self-samples using vaginal swabs 
(every week for HPV+ and  every second week for HPV-), 
to measure vaginal pH and to fill in a short questionnaire. 
Self-samples are stored in the participants’ freezer and 
brought back at every visit.
The study will end with the last HPV+ participant having 
cleared the infection or been infected for 24 months.
Patients and public involvement
Participants did not play a role in the design of this study 
and the results of the study will be disseminated to partic-
ipants who have left the study and to the general public 
via an email newsletter in French.
Visits
The summary of the visit schedule and of the samples 
collected at each visit is shown in table 1.
Inclusion visit (V1)
This visit takes place at the CeGIDD and is scheduled by 
the Clinical Research Technician (CRT) via phone or 
email.
Women meet a study investigator, who explains the 
goals and requirements of the study and checks that the 
inclusion criteria are met. If so, after a general discussion, 
the informed consent forms are signed.
A female physician/midwife performs a general exam 
and then a gynaecological exam during which the 
following samples are taken:
 ► Vaginal pH cotton swab (EcoCare).
 ► Vaginal swab (Copan ESwab) in 1 mL Amies liquid for 
DNA extraction and microbiota analysis.
 ► Vaginal swab (Copan ESwab) in 1 mL of RNA preser-
vation medium.
 ► Ophthalmic sponge (Weck-cel) to collect cervical 
secretions for cytokines analysis.
 ► Cervical smear in 20 mL of PreservCyt liquid (Thin-
prep test) for HPV and HSV assays, and cytology 
evaluation.
Following the gynaecological consultation, the partic-
ipant meets with a nurse to measure body temperature, 
blood pressure and draw 20 mL of blood (a 5 mL tube for 
single nucleotide polymorphisms (SNP) genotyping, a 
10 mL tube for immunophenotyping and a 5 mL tube for 
HPV antibody titration). For the longitudinal study, the 
nurse provides the participant with three self-sampling 
kits, three pH strips, a freezer box to bring back to the 
next visit and instructions on how to perform the home 
sampling and store the samples in her personal freezer 
until the next visit.
If the participant has not been tested for STIs in the 
last 3 months, the nurse draws an additional blood tube 
of 5 mL to test for STIs (HIV, hepatitis C virus, hepatitis 
Figure 1 General structure of the PAPCLEAR study. For the longitudinal study, participants have an inclusion visit (V1), a 
results visit (V2) and then return visits (Vi with i>2). For the cross-sectional study, participants only have V1 and V2. HPV, human 
papillomavirus; STI, sexually transmitted infection. 
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B virus) and collects vaginal self-samples for chlamydiae 
and gonorrhoea detection. Syphilis testing is prescribed 
to participants who meet the STI clinic’s guidelines.
Finally, the participant meets with the CRT to fill in 
questionnaires #1 (inclusion visit) and #3 (home). The 
CRT answers any remaining questions, explains how to 
fill the home questionnaires (#3) and sets an appoint-
ment for the Results visit.
Results visit (V2)
During this visit, the participants are given the result 
of cervical lesion screening using the liquid cytology 
(normal, ASCUS, LSIL or HSIL). Participants with a high-
grade lesion (HSIL) exit the study and are referred to 
the gynaecology service of the Centre Hospitalier Univer-
sitaire (CHU) of Montpellier.
During this visit, the physician/midwife collects addi-
tional samples: two vaginal swabs for DNA and RNA anal-
ysis, and a cervical smear in 5 mL of PBS (to confirm HPV 
status and perform flow cytometry analyses).
The participant fills in questionnaires #2 (for return 
visits) and #3 (home). An appointment for the next visit 
is set and swabs for home self-sampling are given.
Return visits (Vi)
These visits only occur in the longitudinal study.
HPV- arm
Participants uninfected by HPV visit the clinic every 4 
months until month 26. During these visits, the same 
samples as in the inclusion visit (V1) are collected by the 
physician/midwife except for the cervical smear, which is 
put in PBS instead of Thinprep.
The nurse only draws blood if a screening test for STIs 
other than HPV is required. The participant then fills in 
questionnaires #2 and #3 and an appointment is set for 
the next visit in 16 weeks.
If an HPV infection is detected in the cervical smear 
collected during this visit, the participant moves to the 
HPV+ arm and the CRT contacts the participant to move 
her appointment forward.
HPV+ arm
Participants infected by HPV visit the clinic every 2 
months. They cannot switch arm and will remain in the 
HPV+ arm until clearance or the end of the study. During 
the visits, the same samples as in the inclusion visit (V1) 
are collected by the physician/midwife except for the 
cervical smear, which is put in PBS instead of PreservCyt.
The nurse then draws 5 mL of blood for HPV anti-
body titration. If this is the first HPV+ visit following 
an HPV- visit, the nurse also draws 10 mL of blood for 
Table 1 Summary of the visit schedules and samples take
Participants
Inclusion (V1) Results (V2) Return (Vi, with i>2)
All All HPV+ HPV-
Time Day 0 +4 weeks +8 weeks +16 weeks
Eligibility ¤
Consent ¤
Gynaecological consult ¤ ¤ ¤ ¤
Vaginal pH cotton swab ¤ ¤ ¤ ¤
two vaginal swab samples (Copan ESwab) ¤ ¤ ¤ ¤
One ophthalmological sponge sample ¤ ¤ ¤
One cervical smear in PreservCyt (cytology) ¤ +
One cervical smear in PBS (Phosphate Buffered Saline) ¤ + ¤
Blood sampling (HPV antibodies) ¤ ¤
Blood sampling (sequencing) ¤
Blood sampling (immunophenotyping) ¤ ⊲
Other STI detection ⋆ ⋆ ⋆ ⋆
Questionnaire #1 (inclusion) ¤
Questionnaire #2 (visit) ¤ ¤ ¤
Questionnaire #3 (home) ¤ ¤ ¤ ¤
Returning self-sampling samples ¤ ¤ ¤
Serious adverse event collection ¤ ¤ ¤
The cross-sectional study only includes the first two columns (V1 and V2). ¤ S amples taken at visits. + P articipants infected by a HR-HPV for 
12  month will have one PBS smear replaced by a Thinprep smear to perform a cytology and check for lesions. ⊲ T his sample is only taken 
at the first HPV + visit of a formerly HPV- participant. ⋆ STI detection will be performed at inclusion unless the participant has been tested 
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immunophenotyping. Finally, if a test for additional STIs 
is needed, the nurse draws 5 mL of blood and collects 
vaginal self-samples for STI detection.
Importantly, if the participant has been infected by a 
HR-HPV for more than 12 months and a cytological anal-
ysis has not been performed within the last 12 months, 
the cervical smear is put in PreservCyt fixation medium, 
instead of PBS, for cytological analysis (cervical lesion 
screening).
Finally, the participant fills in questionnaires #2 and #3, 
receives self-samples for home collection and an appoint-
ment is set for the next visit in 8 weeks.
Endpoints
The primary endpoint for the study is the inclusion and 
follow-up of HPV-infected women in order to describe the 
kinetics of HPV virus load, and the associated immune 
response.
Secondary endpoints are the characterisation of the 
interactions between the course of the infection (eg, 
duration), the HPV type(s), the abundance and taxo-
nomic diversity of bacteria, fungi and viruses in the 




DNA extraction from cervical smears will be performed 
using Nuclisens easyMAG from Biomerieux or an equiv-
alent protocol. For the microbiota analyses, special kits 
involving physical (via beads) and/or enzymatic breaking 
of the cellular barrier will be favoured following standard 
protocols to study the vaginal microbiome,37 for example, 
the MagAttract PowerMicrobiome DNA/RNA kit from 
Qiagen.
HPV detection, typing and quantification
The participants’ infection status (HPV+ or HPV-) will 
be assessed using a DNA enzyme immunoassay (DEIA) 
detection test based on a PCR of the short SPF10 ampl-
icon38, which detects all Alphapapillomaviruses with great 
sensitivity.
If the DEIA test is positive, HPVs will be typed using the 
LiPA25 kit which is based on the same SPF10-PCR, and has 
a lower detection threshold compared with other hybridi-
sation-based typing methods.39
The reason for basing the detection on the DEIA 
rather than the LiPA25 is that some Alphapapillomavirus 
may be detected by DEIA but not genotyped by LiPA and 
also that the DEIA is more sensitive than the LiPA. If the 
DEIA is positive and the LiPA25 is negative, typing will be 
performed by sequencing the product of a PGMY09/11 
PCR40 which targets another region of the HPV genome 
than the SPF10 PCR.
The quantification of HPV DNA genome copy number 
in the samples will be performed using the qPCR protocol 
set up by Micalessi et al.41
Cytokine titration
Cytokines can be used as markers of immune activation 
or immunosuppression and can also inform us on which 
components of the immune system are involved. Cervical 
sponges are centrifuged after the addition of 175µL of 
PBS. Cervical secretions are analysed for a set of 5 to 6 
cytokines levels using the Meso Scale Discovery Multiplex 
ELISA platform which has a low detection threshold and 
a slowly saturating dose–response curve. Based on earlier 
results,42 43 we will first investigate a large panel of 20 
cyctokines to choose the most relevant ones for a longitu-
dinal follow-up.
Flow cytometry
Analysing immune cells via flow cytometry is extremely 
challenging on cells as fragile as the ones from cervical 
smears. However, several studies suggest that this is 
feasible.42–44 Here, we follow the protocol described 
in Ref 45.
Staining is performed using a Duraclone custom mix 
targeting CD45, CD3, CD4, CD8, CD16, CD56, CD69, 
CD161 and TCRγδ. The last marker, Live&Dead tests for 
cellular viability. Samples are acquired using a Navios flow 
cytometer (Beckman Coulter, three-laser configuration).
Sequencing
Sequencing will be performed for microbiota profiling. 
It involves PCR amplification of the V3-V4 region of 16S 
RNA for bacteria46 and ITS1 for fungi.47 We anticipate 
that the bacteria should belong to the operational taxo-
nomic units (OTU) described in the five community state 
types found in vaginal communities.48 49 The virome will 
also be explored using shotgun sequencing and rolling 
circle PCR amplification.50 Human genetics are explored 
using chip sequencing for SNPs.
statistical analyses
Times series analyses
The core results of the study will come from the longi-
tudinal follow-up of infected women which will generate 
time series (ie, a set of values collected from the same 
individual over time) (figure 2). There will be several 
time series per individual (virus load, number of immune 
cells, cytokine and antibody levels). These time series 
will be used to fit mathematical viral kinetics models that 
describe the interaction between viruses, host target cells 
(here, in the case of HPV, keratinocytes) and the immune 
response. These models are commonly developed for viral 
infections,14 51–53 including those caused by HPVs.54 We 
anticipate our follow-up to yield adequate data for such 
a fit based on the estimated duration of HPV infections 
(9–18 months6 8–10). Furthermore, the weekly self-samples 
allow us to increase the resolution if necessary.
We will use non-linear mixed effect models55 to jointly 
analyse time series from all participants. More precisely, 
we will rely on R packages such as nlme56 or lme4.56 Note 
that, in addition to estimating model parameters (eg, 
life-expectancy of infected cells or virion production rate 
 o
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of infected cells), this approach also allows us to compare 
biological models using statistical tools based on model 
likelihood such as Akaike Information Criterion. For an 
example of such analysis in the case of HIV, see Ref.52
Microbiota dynamics
The composition of the vaginal microbiota has already 
been described and shown to exhibit considerably less 
diversity than the gut microbiota.48 The dynamics of this 
microbiota has also been studied and shown to closely 
follow menstrual cycles.49
Using the time series of OTU abundances (measured 
via 16S RNA sequencing and qPCR) we will infer inter-
action parameters by assuming an underlying Lotka-Volt-
erra competition model.57 This work will include time 
series analysis techniques (eg, auto-correlation or local 
similarity analysis) and statistical inference methods in 
order to infer community structure and interactions from 
the next-generation sequencing (NGS) datasets.58 Finally, 
statistical methods from ecology will also be used to study 
community diversity (eg, diversity indices) and commu-
nity assembly, such as cluster and ordination analyses.59
Genome wide association studies
We will use human SNPs inferred by chip sequencing to 
look for genetic determinants of key traits (e.g., micro-
biota composition or HPV infection duration). This is 
classically done by performing a Genome Wide Asso-
ciation Study (GWAS), which is a complex regression 
method designed for situations where there are many 
explanatory variables (here millions of SNPs) for a single 
trait of interest. GWAS will be performed using classical 
methods.60 Earlier GWAS studies have been applied to 
HPV infections for instance to test for determinants 
to the ability to seroconvert following infection61 and 
cervical cancer (see62 for a review). Here, our expected 
sample (n=300 women) is limited but SNPs with large 
effects have been detected by studies with comparable 
sizes.63
Additional analyses
For all collected variables, descriptive statistics will be 
calculated according to the level of measurement. For 
metric variables these statistics can be mean and SD as 
well as quantiles and more robust statistics.64 In case of 
categorical variables group proportions and contingency 
tables are prepared.
Univariate inferential statistics follow a descriptive 
analysis. Generally, parametric testing procedures are 
preferred to non-parametric tests, as the former have 
higher power. That is why, for metric variables, we will first 
check whether the data can be assumed to be normally 
distributed. For normally distributed variables, analysis of 
variance statistics are done to detect differences between 
groups. In case of significance, post-hoc analysis (Tukey 
test) are planned to reveal pairwise differences. If the 
data are not normally distributed or ordinally scaled, 
non-parametric analyses will be used. These contain the 
Kruskal-Wallis test and the Wilcoxon test as a post-hoc 
test with an appropriate correction of the significance 
level. Since the cell counts are expected to be small, Fish-
er’s exact test will be performed for contingency tables 
instead of the asymptotic χ2 test for categorical variables.
sample size calculation
The study will enrol a total of n=300 women, with n=150 in 
a longitudinal study and n=150 in a cross-sectional study. 
The goal of the longitudinal study is to follow 75 women 
longitudinally, preferentially before they are infected (see 
above). For the following calculations, we assumed a high 
percentage of lost during follow-up (30%).
With 150 enrolments and considering that the preva-
lence of HPV infection in young women is ≈60% (based 
on our preliminary data) and 30% of lost to follow-up, we 
expect to detect (and successfully follow) 63 infections at 
inclusion (95% CI: 51 to 75, assuming a binomial distri-
bution to calculate the 95% CI).
Among women who are uninfected at the first visit and 
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Figure 2 Fitting viral kinetics models to within-host times series. Dashed lines indicate a model fitted using virus load (in 
black) or immune cells (in red) time series. In panel A, the follow-up is bi-monthly with two missing visits and several delayed 
visits, whereas in panel B the follow-up is every 4 months without any missing or delayed visits. In spite of missing data this, the 
situation shown in panel A is clearly the best for inferring parameter values and for fitting the underlying dynamics.
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expect 12 (95% CI 6 to 20) to be infected during the first 
year of follow-up (still assuming 30% of lost to follow-up).
In the end, with 150 enrolments and assuming a high 
percentage of lost to follow-up (30%), we expect to success-
fully follow 75 (95% CI 56 to 95) women infected at different 
stages of HPV infection: beginning, during and end.
This will be made possible by the probability of trans-
mission of HPV, which is estimated to be ≈90% without 
condom use and still high with condom use (≈40%).35
Finally, regarding potential interference with the HPV 
vaccines, we do not anticipate any significant problem 
for two reasons. First, as mentioned above, the vaccine 
coverage is low in France.33 Second, and more impor-
tantly, the vaccines only target few HPV types, thus leaving 
open the possibility of infection by dozens of types. 
Furthermore, studying the kinetics of a non-vaccine HPV 
type in a vaccinated woman will be extremely informative 
(eg, to detect any potential cross-reactivity).66
To run cross-sectional analyses (especially on the micro-
biota and human genetics), we will enrol n=150 addi-
tional women who will only perform the inclusion and 
the results visits. This sample size was chosen to reach that 
of earlier GWAS studies.62 63
trial governance
Sponsor
This study is sponsored by the CHU of Montpellier. The 
CHU is involved in the implementation of the trial, legal/
ethical submissions (see Ethics approval statement) and 
implementing the clinical database online Case Report 
Form (eCRF) which is hosted by Ennov-Clinical (ClinSight). 
The CHU is not involved in the analysis or interpretation of 
the data. The CHU of Montpellier performs regular quality 
control assessments. A clinical research assistant will visit 
the CeGIDD every 4 months to ensure that implementa-
tion is in accordance with the protocol. The CHU has taken 
out insurance from the Société hospitalière d’assurances 
mutuelles, 18, rue Edouard Rochet-6 9372 Lyon cedex 08 
(contract number 138983) through the full research period, 
covering its own civil liability and that of any agent (clinical 
or research staff), in accordance with article L.1121–10 of 
the French Public Health Code.
Scientific committee
The scientific committee comprises the study investiga-
tors, clinicians, scientific experts and representatives of 
the sponsor. The committee meets yearly and is respon-
sible for following research progress, monitoring compli-
ance with good clinical practices and patient safety. It 
can also decide relevant modification of the protocol. 
Requests from third parties to access data collected 
during the study will be evaluated by the committee.
Monitoring
Monitoring is performed during the whole study at 
CeGIDD according to the sponsor specific SOP. Routine 
monitoring visits are made by the monitors designated by 
the sponsor to check compliance with the protocol, the 
completeness, accuracy and consistency of the data and 
adherence to GCP. The principal investigator ensures that 
eCRFs are completed in a timely manner and must allow 
periodical access to eCRFs, patient records, drug logs 
and all other study-related documents and materials. The 
frequency of monitoring visits is determined by factors 
such as study design and the site enrolment requirements 
but visits will normally occur at least once every 4 months.
Ethics and dissemination
The protocol has been modified since its initial version 
and the latest modification was accepted by the Comité 
de Protection des Personnes on 12 December 2018.
All participants in the study will sign an informed 
consent form prior to participation.
The results will be published on preprint servers (eg, 
BioRxiv), peer-reviewed journals, postprint servers (e.g., 




Acute infections by HPVs are important to study because 
vaccination is most effective when performed before the 
first infection. However, we currently know very little about 
the early stages of HPV infections. This clinical study will 
give us an unprecedented level of detail into the natural 
history of HPV infections in young women. Variations in 
virus load over time have been studied but in the context 
of cervical cancer in older women.67 In addition, we will 
also describe the nature and the dynamics of the immune 
response (local immune cells and cytokines, circulating 
anti-HPV antibodies) and of the vaginal microbiota. Beyond 
these kinetics, we will also have access to data such as infec-
tion clearance or not in 24 months, presence of more than 
one HPV type or coinfection by other STIs.
These data will be analysed in the light of numerous 
cofactors. One of the most important will be human 
genetics, with the sequencing of millions of SNPs. Others 
will be related to the sexual behaviour (number of part-
ners, contraception methods, sexual practices) and 
general lifestyle. We, therefore, expect broader insights 
regarding sexual health in young women.
Practical and operational issues
One of the main practical challenges resides in the anal-
ysis of cervical smears by flow cytometry. Indeed, the 
tissues are known to be fragile, adhesive and auto-fluo-
rescent. Even though standard protocols now exist,45 they 
require processing fresh samples in less than 2 hours.
Another potential issue has to do with contamination 
by HPV DNA between samples, which are frequent in 
the HPV field due to the robustness of the virions and 
the sensitivity of the tests. To certify our ability to control 
for these, we have entered the 2017 GLOBAL HPV DNA 
Proficiency Panel from the WHO HPV LabNet.68
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Regarding the enrolment of the participants, we do not 
expect issues with enrolling 150 women in 28 months for 
the longitudinal study and 150 for the cross-sectional study. 
This is due to the number of visitors of the centre who fit the 
inclusion criteria (more than 3000 per year) and because of 
earlier high participation rates in the same population (34 
enrolled 1381 participants in 5 months for their study).
Concerning the follow-up, the high incidence rate of 
HPV can also lead to transient carriage, that is, women 
who are positive for a type only at a single visit. This has 
been observed for instance in longitudinal studies with 
a tight follow-up interval.22 To control for this, we will 
run the HPV detection test on the cells from the cervical 
smear after washing with RPMI. 
trial status
The study began on 1 October 2016 and the first inclusion 
was on 3 November 2016. On 23 June 2018, 89 partici-
pants have been included in the longitudinal study. Inclu-
sions in the longitudinal study will continue until March 
2019 and the study is expected to last until August 2021.
Author affiliations
1MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France
2Center for Free Information, Screening and Diagnosis (CGIDD), Centre Hospitalier 
Universitaire de Montpellier, Montpellier, France
3Department of Obstetrics and Gynaecology, Centre Hospitalier Universitaire de 
Montpellier, Montpellier, France
4Department of Research and Innovation (DRI), Centre Hospitalier Universitaire de 
Montpellier, Montpellier, France
5CIBER en Epidemiología y Salud Pública (CIBEResp), Madrid, Spain
6Sequencing and Bioinformatics Service, Fundaciónpara el Fomento de la 
Investigación Sanitaria y Biomédica de laComunidad Valenciana (FISABIO-Salud 
Pública), Valencia, Spain
7Pathogenesis and Control of Chronic Infections, INSERM, CHU, University of 
Montpellier, Montpellier, France
8Department of Virology, Centre Hospitalier Universitaire de Montpellier, Montpellier, 
France
9LBPC/PPC- IRMB, CHU de Montpellier and Université de Montpellier, Montpellier, 
France
10Department of Medical Information (DIM), Centre Hospitalier Universitaire de 
Montpellier, Montpellier, France
11Department of Medical microbiology, University of Manitoba, Winnipeg, Manitoba, 
Canada
12Department of pathology and oncobiology, Centre Hospitalier Universitaire de 
Montpellier, Montpellier, France
13Institute for Genome Sciences, University of Maryland School of Medicine, 
Baltimore, Maryland, USA
14Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire de 
Montpellier, Montpellier, France
15German Cancer Research Center (DKFZ), Infections and Cancer Epidemiology, 
Heidelberg, Germany
16GIGA-Research, Cellular and molecular immunology, University of Liège, Liège, 
Belgium
Acknowledgements We thank all the study participants and the CeGIDD staff 
for their commitment to the study. We also thank the reviewers and, in particular, 
Dr Andrew Brouwer for his meticulous reading of the manuscript. 
Contributors SA, CLM and MR were the major contributors in the conception of 
the protocol. SA wrote the initial version of the manuscript. CS, MBaldellou, CB, 
MBonneau, VBé, MBuisson, GC, GD’A, FDT, VF, RéF, CG, SGrasset, SGroc, CH, AJ, JL, 
FL, EP, M-CP, JRa, JRe, TR, AS, MT, VT, ÉT, TW, NJ, IGB, MS and NB were involved 
in the conception of the protocol, in the implementation of the study and read and 
approved the final manuscript.
Funding This project has received funding from the European Research 
Council (ERC) under the European Union’s Horizon 2020 research and innovation 
programme (grant agreement No 648963). The authors acknowledge further 
support from the Centre National de la Recherche Scientifique (CNRS), the Institute 
de Recherche pour le Développement (IRD) and the Centre Hospitalier Universitaire 
(CHU) of Montpellier. 
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The PAPCLEAR trial obtained favourable opinions from the 
Comité de Protection des Personnes (CPP) Sud Méditerranée I on 11 May 2016 
(CPP number 16 42, reference number ID RCB 2016-A00712-49); from the Comité 
Consultatif sur le Traitement de l’Information en matière de Recherche dans le 
domaine de la Santé on 12 July 2016 (reference number 16.504); and from the 
Commission Nationale Informatique et Libertés on 16 December 2016 (reference 
number MMS/ABD/AR1612278, decision number DR-2016–488). This trial was 
authorised by the Agence Nationale de Sécurité du Médicament et des Produits de 
Santé on 20 July 2016 (reference 20160072000007).
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Tota JE, Chevarie-Davis M, Richardson LA, et al. Epidemiology 
and burden of HPV infection and related diseases: implications for 
prevention strategies. Prev Med 2011;53(Suppl 1):S12–S21.
 2. Chesson HW, Dunne EF, Hariri S, et al. The estimated lifetime 
probability of acquiring human papillomavirus in the United States. 
Sex Transm Dis 2014;41:660–4.
 3. Monsonego J, Zerat L, Syrjänen K, et al. [Prevalence of genotype-
specific HPV infection among women in France: implications for 
screening and vaccination]. Gynecol Obstet Fertil 2013;41:305–13.
 4. Brun-Micaleff E, Coffy A, Rey V, et al. Cervical cancer screening 
by cytology and human papillomavirus testing during pregnancy in 
French women with poor adhesion to regular cervical screening. J 
Med Virol 2014;86:536–45.
 5. Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus 
prevalence in 5 continents: meta-analysis of 1 million women with 
normal cytological findings. J Infect Dis 2010;202:1789–99.
 6. Insinga RP, Dasbach EJ, Elbasha EH, et al. Incidence and duration of 
cervical human papillomavirus 6, 11, 16, and 18 infections in young 
women: an evaluation from multiple analytic perspectives. Cancer 
Epidemiol Biomarkers Prev 2007;16–709–15.
 7. Woodman CB, Collins SI, Young LS. The natural history of cervical 
HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11–22.
 8. Rodríguez AC, Schiffman M, Herrero R, et al. Proyecto 
Epidemiológico Guanacaste Group: Rapid clearance of human 
papillomavirus and implications for clinical focus on persistent 
infections. J Natl Cancer Inst 2008;100:513–7.
 9. Trottier H, Mahmud S, Prado JC, et al. Type-specific duration 
of human papillomavirus infection: implications for human 
papillomavirus screening and vaccination. J Infect Dis 
2008;197:1436–47.
 10. Ramanakumar AV, Naud P, Roteli-Martins CM, et al. Incidence and 
duration of type-specific human papillomavirus infection in high-risk 
HPV-naïve women: results from the control arm of a phase II HPV-
16/18 vaccine trial. BMJ Open 2016;6:011371.
 11. Houlihan CF, Baisley K, Bravo IG, et al. Rapid acquisition of HPV 
around the time of sexual debut in adolescent girls in Tanzania. Int J 
Epidemiol 2016;45:762–73.
 12. Alizon S, Murall C, Bravo I. Why Human Papillomavirus Acute 
Infections Matter. Viruses 2017;9:293.
 13. Herrero R, Wacholder S, Rodríguez AC, et al. Prevention of 
persistent human papillomavirus infection by an HPV16/18 vaccine: 
a community-based randomized clinical trial in Guanacaste, Costa 
Rica. Cancer Discov 2011;1:408–19.
 14. Canini L. Perelson, A.S.: Viral kinetic modeling: state of the art. J 
Pharmacokinet Pharmacodyn 2014;41:431–43.








pen: first published as 10.1136/bmjopen-2018-025129 on 11 June 2019. Downloaded from 
10 Murall CL, et al. BMJ Open 2019;9:e025129. doi:10.1136/bmjopen-2018-025129
Open access 
 16. Ferenczy A, Franco E. Persistent human papillomavirus infection and 
cervical neoplasia. Lancet Oncol 2002;3:11–16.
 17. Hausen zur. H.: Review: Papillomaviruses — to Vaccination and 
Beyond. Biochemistry 2008;73:498–503.
 18. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human 
papillomavirus immunology: knowns and unknowns. Lancet Infect 
Dis 2009;9:347–56.
 19. Van Hede D, Langers I, Delvenne P, et al. Origin and immunoescape 
of uterine cervical cancer. Presse Med 2014:43:413–21.
 20. Stanley M. Immunology of HPV Infection. Curr Obstet Gynecol Rep 
2015;4:195–200.
 21. Gao W, Weng J, Gao Y, et al. Comparison of the vaginal microbiota 
diversity of women with and without human papillomavirus infection: 
a cross-sectional study. BMC Infect Dis 2013;13:271.
 22. Brotman RM, Shardell MD, Gajer P, et al. Interplay between 
the temporal dynamics of the vaginal microbiota and human 
papillomavirus detection. J Infect Dis 2014;210:1723–33.
 23. Koutsky LA, Ault KA, Wheeler CM, et al. Proof of Principle Study 
Investigators: A controlled trial of a human papillomavirus type 16 
vaccine. N Engl J Med 2002;347:1645–51.
 24. Riethmuller D, Jacquard AC, Lacau St Guily J, et al. Potential impact 
of a nonavalent HPV vaccine on the occurrence of HPV-related 
diseases in France. BMC Public Health 2015;15:453.
 25. Joura EA, Giuliano AR, Iversen O-E, et al. Broad Spectrum HPV 
Vaccine Study: A 9-valent HPV vaccine against infection and 
intraepithelial neoplasia in women. N Engl J Med 2015;372:711–23.
 26. Murall CL, Bauch CT, Day T. Could the human papillomavirus 
vaccines drive virulence evolution? Proc Biol Sci 
2015;282:20141069.
 27. Alizon S, Méthot PO. Reconciling Pasteur and Darwin to control 
infectious diseases. PLoS Biol 2018;16:e2003815.
 28. Moscicki A-B, Ma Y, Wibbelsman C, et al. Shiboski, S.: Rate of and 
Risks for Regression of CIN-2 in adolescents and young women. 
Obstet Gynecol 2010;116:1373–80.
 29. Buck Jr. H.W. Warts (genital). BMJ Clin Evid 2015:1602.
 30. Herrero R, González P, Markowitz LE. Present status of human 
papillomavirus vaccine development and implementation. Lancet 
Oncol 2015;16:e206–e216.
 31. Maver PJ, Poljak M. Progress in prophylactic human papillomavirus 
(HPV) vaccination in 2016: A literature review. Vaccine 
2018;36:5416–23.
 32. Fagot JP, Boutrelle A, Ricordeau P, et al. HPV vaccination in France: 
uptake, costs and issues for the National Health Insurance. Vaccine 
2011;29:3610–6.
 33. Ben Hadj Yahia M-B, Dervaux B, Duport N, et al. Vaccination contre 
les infections à papilloamvirus. Paris, France: Technical report, Haut 
Conseil de la Santé Publique, 2014.
 34. Clarivet B, Picot E, Marchandin H, et al. Prevalence of Chlamydia 
trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium 
in asymptomatic patients under 30 years of age screened in 
a French sexually transmitted infections clinic. Eur J Dermatol 
2014;24:611–6.
 35. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of 
genital human papillomavirus infection in young women. N Engl J 
Med 2006;354:2645–54.
 36. Winer RL, Hughes JP, Feng Q, et al. Incident Detection of High-Risk 
Human Papillomavirus Infections in a Cohort of High-Risk Women 
Aged 25-65 Years. J Infect Dis 2016;214:665–75.
 37. Ravel J, Brotman RM, Gajer P, et al. Daily temporal dynamics of 
vaginal microbiota before, during and after episodes of bacterial 
vaginosis. Microbiome 2013;1:29.
 38. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment 
PCR assay for highly sensitive broad-spectrum detection of 
anogenital human papillomaviruses. Am J Pathol 1998;153:1731–9.
 39. Geraets DT, Struijk L, Kleter B, et alColau, B.: The original SPF10 
LiPA25 algorithm is more sensitive and suitable for epidemiologic 
HPV research than the SPF10 INNO-LiPA Extra.  J Virol Meth 
2015:216:22–9.
 40. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of 
genital human papillomaviruses. J Clin Microbiol 2000;38:357–61.
 41. Micalessi IM, Boulet GAV, Bogers JJ, et al. High-throughput 
detection, genotyping and quantification of the human papillomavirus 
using real-time PCR. Clin Chem Lab Med 2012;50:655–61.
 42. Hunter PJ, Sheikh S, David AL, et al. Cervical leukocytes and 
spontaneous preterm birth. J Reprod Immunol 2016;113:42–9.
 43. Shannon B, Yi TJ, Perusini S, et al. Association of HPV infection 
and clearance with cervicovaginal immunology and the vaginal 
microbiota. Mucosal Immunol 2017;10:1310–9.
 44. Lajoie J, Juno J, Burgener A, et al. A distinct cytokine and chemokine 
profile at the genital mucosa is associated with HIV-1 protection 
among HIV-exposed seronegative commercial sex workers. Mucosal 
Immunol 2012;5:277–87.
 45. Juno JA, Boily-Larouche G, Lajoie J, et al. Collection, isolation, and 
flow cytometric analysis of human endocervical samples. J Vis Exp 
2014;89:51906.
 46. Frank JA, Reich CI, Sharma S, et al. Critical evaluation of two primers 
commonly used for amplification of bacterial 16S rRNA genes. Appl 
Environ Microbiol 2008;74:2461–70.
 47. Findley K, Oh J, Yang J, et al. NIH Intramural Sequencing Center 
Comparative Sequencing Program, Kong, H.H., Segre, J.A.: 
Topographic diversity of fungal and bacterial communities in human 
skin. Nature 2013;498:367–70.
 48. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-
age women. Proc Natl Acad Sci U S A 2011;108 Suppl 1:4680–7.
 49. Gajer P, Brotman RM, Bai G, et al. Temporal dynamics of the human 
vaginal microbiota. Sci Transl Med 2012;4:132ra52–52.
 50. Johne R, Müller H, Rector A, et al. Rolling-circle amplification of 
viral DNA genomes using phi29 polymerase. Trends Microbiol 
2009;17:205–11.
 51. Nowak MA, May R. M.: Virus Dynamics: Mathematical Principles of 
Immunology and Virology. Oxford, USA: Oxford University Press, 
2000.
 52. Stafford MA, Corey L, Cao Y, et al. Modeling plasma virus 
concentration during primary HIV infection. J Theor Biol 
2000;203:285–301.
 53. Perelson AS. Modelling viral and immune system dynamics. Nat Rev 
Immunol 2002;2:28–36.
 54. Murall CL, Jackson R, Zehbe I, et al. Epithelial stratification shapes 
infection dynamics. PLoS Comput Biol 2019;15:e1006646.
 55. Steimer JL, Vozeh S, Racine Poon A, et al. Handbook of Experimental 
Pharmacology. Balant P, O’Neil, R.: The population approach: 
rationale, methods and applications in clinical pharmacology and 
drug development. . Berlin : Springer, 1994:110. 405–51.
 56. Bates D, Mächler M, Bolker B, et al. Walker, S.: Fitting linear mixed-
effects models using lme4. Journal of Statistical Software 2015;67.
 57. Bucci V, Tzen B, Li N, et al. MDSINE: Microbial Dynamical Systems 
INference Engine for microbiome time-series analyses. Genome Biol 
2016;17:121.
 58. Faust K, Lahti L, Gonze D, et al. Metagenomics meets time series 
analysis: unraveling microbial community dynamics. Curr Opin 
Microbiol 2015;25:56–66.
 59. Fox GA, Negrete-Yankelevich S, Sosa V. J.: Ecological Statistics: 
Contemporary Theory and Application. Oxford University Press. 
Oxford, USA: Oxford University Press, 2015.
 60. Shi Y, Li L, Hu Z, et al. A genome-wide association study identifies 
two new cervical cancer susceptibility loci at 4q12 and 17q12. Nat 
Genet 2013;45:918–22.
 61. Chen D, Gaborieau V, Zhao Y, et al. A systematic investigation of 
the contribution of genetic variation within the MHC region to HPV 
seropositivity. Hum Mol Genet 2015;24:2681–8.
 62. Chen D, Gyllensten U. Lessons and implications from association 
studies and post-GWAS analyses of cervical cancer. Trends Genet 
2015;31:41–54.
 63. Fellay J, Shianna KV, Ge D, et al. A whole-genome association 
study of major determinants for host control of HIV-1. Science 
2007;317:944–7.
 64. Huber PJ. The 1972 Wald Lecture Robust Statistics: A Review. The 
Annals of Mathematical Statistics 1972;43:1041–67.
 65. Winer RL, Feng Q, Hughes JP, et al. Risk of female human 
papillomavirus acquisition associated with first male sex partner. J 
Infect Dis 2008;197:279–82.
 66. Herrero R. Human papillomavirus (HPV) vaccines: limited 
cross-protection against additional HPV types. J Infect Dis 
2009;199:919–22.
 67. Depuydt CE, Verstraete L, Berth M, et al. Human Papillomavirus 
Positivity in Women Undergoing Intrauterine Insemination Has 
a Negative Effect on Pregnancy Rates. Gynecol Obstet Invest 
2016;81:41–6.
 68. HPV LabNet WHO. World Health Organization. 2008 http://www. who. 
int/ biologicals/ areas/ human_ papillomavirus/ WHO_ HPV_ LabNet/ en/.
 o
n




pen: first published as 10.1136/bmjopen-2018-025129 on 11 June 2019. Downloaded from 
